Pharmacodynamic Studies

OTHER2 trials

Sponsors

Amir Mortazavi, Ohio State University Comprehensive Cancer Center

Conditions

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHematopoietic/Lymphoid CancerHepatosplenic T-cell Lymphoma

Phase 1

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

CompletedNCT01129193

Amir MortazaviAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma +64

Start: 2010-05-04End: 2017-01-07Updated: 2018-06-04

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

CompletedNCT01212380

Ohio State University Comprehensive Cancer CenterB-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia +2

Start: 2010-10-31End: 2015-09-30Updated: 2016-05-09

Related Papers

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.

2021-10-073 citations

Early phase clinical studies of <scp>AR</scp>‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

Laryngoscope Investigative Otolaryngology2021-08-2036 citations

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

2021-01-2518 citations

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Leukemia & lymphoma/Leukemia and lymphoma2017-03-0755 citations

A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.

Journal of Clinical Oncology2016-05-204 citations